
Claims:

1. A compound of Formula (I):



(I)

wherein

R_1 is selected from the group consisting of: C_1-C_6alkyl, -NSO_2Me, -NSO_2Ph, arylalkoxy, C_3-C_7cycloalkyl, -$NC(O)R_a$, 1-methyl-1H-pyrazol-4-yl, hydroxyl, C_1-C_4alkoxy, halogen, amide, amino, substituted amino, and -$C(O)OR_a$;

R_2 is hydrogen or COOH;

each R_3 is independently selected from the group consisting of: aryl, heteoaryl, hydrogen, C_1-C_6alkyl, -SO_2R_a, -$NC(O)R_a$, -$CH_2C(O)OR_a$, -$C(O)OR_a$, -$C(O)R_a$, -$C(O)NR_aR_b$, substituted amino, amino, urea, amide, sulfonamide, arylalkyl, and heteroarylalkyl;

each R_a is independently hydrogen, phenyl, phenylmethyl, 3,5-dimethylisoxazol-4-yl, 1,2-dimethyl-1H-imidazol-4-yl, C_3-C_7cycloalkyl, C_1-C_6alkyl, C_1-C_4alkoxy, C_1-C_3alkylamino, or -NHPh;

R_b is hydrogen or C_1-C_3alkyl, or when attached to the same atom; or

R_a and R_b together form a 5- or 6-membered hetercycloalkyl ring;

R_4 is C_1-C_4alkyl, acyl, -C(O)CF_3 or hydrogen;

W is -$(CH_2)_{1-4}$, or –$CH(R_c)(CH_2)_{0-3}$, in which R_c is CN or C_1-C_4alkyl;

Y is N or C;

X is N or C;

Z is O or $(CH_2)_q$, wherein q is 0-2, when q is 0, Z represents a bond;


m is 0-3, n is 0-3;

provided that when Z is O, Y is N and X is C;

also provided that when X is C, at least one of the R_3 groups attached to X is not hydrogen;

or a pharmaceutically acceptable salt thereof.


2. A compound of claim 1 which is represented by Formula (II):



(II);

wherein R_1-R_4, m, W, Y, X and X are defined as in claim 1;
or a pharmaceutically acceptable salt thereof.

3. A compound of claim 1, which is represented by Formula (III):




(III);

wherein R_1-R_4, m, W, Y, X and X are defined as in claim 1;

or a pharmaceutically acceptable salt thereof.

4. A compound according to any one of claims 1-3, wherein Z is CH; or a pharmaceutically acceptable salt thereof.
5. A compound according to any one of claims 1-3, wherein X is C, Y is N and Z is O; or a pharmaceutically acceptable salt thereof.
6. A compound according to any one of claims 1-3, which is represented by formula (IV):



(IV);


wherein

Z is $(CH_2)_q$, wherein q is 0-2, when q is 0, Z represents a bond;

m is 0-3;

W, X, R_1, R_3 and R_4 are defined according to claim 1; or a pharmaceutically acceptable salt thereof.

7. A compound according to any one of claims 1-3, which is represented by formula (V):



(V);

wherein

Z is $(CH_2)_q$, wherein q is 0-2, when q is 0, Z represents a bond;

W, X, R_1, R_3 and R_4 are defined according to claim 1; or a pharmaceutically acceptable salt thereof.

8. A compound according to any one of the above claims, wherein R_4 is H and X is N; or a pharmaceutically acceptable salt thereof.
9. A compound according to any one of the above claims, wherein R_1 is F, Cl, C_1-C_4alkoxy, or C_1-C_4alkyl; or a pharmaceutically acceptable salt thereof.
10. A compound according to any one of the above claims, wherein m is 0; or a pharmaceutically acceptable salt thereof.


11. A compound according to any one of the above claims, wherein each R_3 is independently selected from the group consisting of: aryl, arylalkyl, heteoaryl, heteroarylalkyl, wherein said aryl and heteroaryl are each optionally substituted with 1-3 groups selected from the group consisting of: -COOH, C_1-C_4alkoxy, -C(O)OC_1-C_4alkyl, C_1-C_4alkyl, halogen, CN, tetrazolyl, -NSO_2Me, -SO_2Me, -C(O)N(CH_2)OH, -C(O)NSO_2Me, -OCH_2COOH; or a pharmaceutically acceptable salt thereof.

12. A compound according to any one of claims 1-10, wherein each R_3 is independently selected from the group consisting of: hydrogen, C_1-C_6alkyl, -

SO_2R_a, $-NC(O)R_a$, $-CH_2C(O)OR_a$, $-C(O)OR_a$ $-C(O)R_a$, $-C(O)NR_aR_b$, substituted amino, amino, urea, amide, sulfonamide, arylalkyl, and heteroarylalkyl, wherein R_a is phenyl, phenylmethyl, C_3-C_7cycloalkyl, C_1-C_6alkyl, C_1-C_4alkoxy, C_1-C_3alkylamino or -NHPh; R_b is hydrogen or C_1-C_4alkyl, or when attached to the same atom, R_a and R_b together form a 5- or 6-membered hetercycloalkyl ring, wherein said phenyl may be substituted with one to three groups selected from the group consisting of: C_1-C_4alkyl, halogen, and COOH; or a pharmaceutically acceptable salt thereof.

13. A compound according to claim 12, wherein each R_3 is independently selected from the group consisting of: hydrogen, C_1-C_6alkyl, $-SO_2R_a$, $-NC(O)R_a$, $-C(O)OR_a$ $-C(O)R_a$, $-C(O)NR_aR_b$, substituted amino, amino, urea, amide, sulfonamide, arylalkyl, and heteroarylalkyl, wherein R_a is phenyl, phenylmethyl, C_3-C_7cycloalkyl, C_1-C_6alkyl, C_1-C_4alkoxy, C_1-C_3alkylamino or -NHPh; R_b is hydrogen or C_1-C_4alkyl; or a pharmaceutically acceptable salt thereof.

14. A compound according to any one of claims 1-3, which is represented by formula (VI):



(VI);


wherein

R_1 and W are defined as in claim 1;

s is 1-2;

each R_5 is independently selected from the group consisting of: -COOH, alkoxy, $-C(O)OC_1$-C_4alkyl, C_1-C_4alkyl, halogen, CN, tetrazolyl, $-NSO_2Me$, $-SO_2Me$, $-C(O)N(CH_2)OH$, $-C(O)NSO_2Me$, $-OCH_2COOH$; or a pharmaceutically acceptable salt thereof.

15. A compound according to any one of claims 1-3, which is represented by formula (VII):



(VII);

wherein

R_1 and W are defined as in claim 1;

s is 1-2;

each R_5 is independently selected from the group consisting of: -COOH, alkoxy, -$C(O)OC_1$-C_4alkyl, C_1-C_4alkyl, halogen, CN, tetrazolyl, -NSO_2Me, -SO_2Me, -$C(O)N(CH_2)OH$, -$C(O)NSO_2Me$, -OCH_2COOH; or a pharmaceutically acceptable salt thereof.

16. A compound of claim 14 or 15, wherein R_5 is –COOH, s is 1; or a pharmaceutically acceptable salt thereof.

17. A compound according to claim 1 selected from the group consisting of:

1,1-Dimethylcthyl 4-({[*trans*-2-phenylcyclopropyl]amino}methyl)-1-piperidinecarboxylate;

1;1-Dimethylethyl 4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)-1-piperidinecarboxylate;

1,1-Dimethylethyl 4-({[(1S,2R)-2-phenylcyclopropyl]amino}methyl)-1-piperidinecarboxylate;

[*trans*-2-Phenylcyclopropyl](4-piperidinylmethyl)amine;

[(1S,2R)-2-Phenylcyclopropyl](4-piperidinylmethyl)amine;

[(1R,2S)-2-Phenylcyclopropyl](4-piperidinylmethyl)amine;

trans-N-(Cyclohexylmethyl)-2-phenylcyclopropanamine;

[*trans*-2-Phenylcyclopropyl]{[1-(phenylmethyl)-4-piperidinyl]methyl}amine;

1,1-Dimethylethyl [*trans*-4-({[trans-2-phenylcyclopropyl]amino}methyl)cyclohexyl]carbamate;

trans-4-({[trans-2-Phenylcyclopropyl]amino}methyl)cyclohexanamine;
2-(4-(((*trans*-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)ethanol;
N-Phenyl-4-(((*trans*-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxamide;
Phenyl(4-(((*trans*-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methanone;
1-(4-(((*trans*-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)ethanone;
[*trans*-2-Phenylcyclopropyl](3-piperidinylmethyl)amine;
N-(*trans*-2-Phenylcyclopropyl)-N-(piperidin-4-ylmethyl)acetamide;
Benzyl 4-(((*trans*-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxylate;
4-(((*trans*-2-Phenylcyclopropyl)amino)methyl)piperidine;
[(1-Methyl-4-piperidinyl)methyl][*trans*-2-phenylcyclopropyl]amine;
1,1-Dimethylethyl 4-({[*trans*-2-phenylcyclopropyl]amino}methyl)hexahydro-1*H*-azepine-1-carboxylate; or a pharmaceutically acceptable salt thereof.
N-(Hexahydro-1*H*-azepin-4-ylmethyl)-trans-2-phenylcyclopropanamine;
[*trans*-2-Phenylcyclopropyl][2-(4-piperidinyl)ethyl]amine;
[*trans*-2-Phenylcyclopropyl][1-(4-piperidinyl)ethyl]amine;
N-(2-Morpholinylmethyl)-*trans*-2-phenylcyclopropanamine;

4-((4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;
2-(4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)acetic acid;
4-{[(3*R*)-3-({[(1*R*,2*S*)-2-Phenylcyclopropyl]amino}methyl)-1-pyrrolidinyl]methyl}benzoic acid ;
4-{[(3*S*)-3-({[(1*R*,2*S*)-2-Phenylcyclopropyl]amino}methyl)-1-pyrrolidinyl]methyl}benzoic acid;
4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;
4-{3-[4-({[(1*R*,2*S*)-2-Phenylcyclopropyl]amino}methyl)-1-piperidinyl]propyl}benzoic acid;
trans-N-((1-Isopropylpiperidin-4-yl)methyl)-2-phenylcyclopropanamine;
trans-N-((1-(2-Methoxyethyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;
trans-2-Phenyl-N-((1-(pyridin-4-ylmethyl)piperidin-4-yl)methyl)cyclopropanamine;
trans-N-((1-(2-Fluorobenzyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

1,1-Bis(2-fluorobenzyl)-4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-ium chloride;
trans-N-((1-(3-Fluorobenzyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;
1,1-Bis(3-fluorobenzyl)-4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-ium chloride;
trans-N-((1-(4-Fluorobenzyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;
1,1-bis(4-Fluorobenzyl)-4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-ium chloride;
trans-N-((1-(2,4-Difluorobenzyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;
1,1-Bis(2;4-difluorobenzyl)-4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-ium bromide;
Ethyl 4-((4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoate;
trans-N-((1-(4-(Methylsulfonyl)benzyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;
1-(4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)butan-2-ol;
2-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzonitrile;
trans-2-Phenyl-N-((1-(2-(trifluoromethyl)benzyl)piperidin-4-yl)methyl)cyclopropanamine;
trans-N-((1-((5-Methylisoxazol-3-yl)methyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;
trans-N-((1-((1H-Pyrazol-4-yl)methyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine
trans-N-((1-Ethylpiperidin-4-yl)methyl)-2-phenylcyclopropanamine;
Diethyl (3-(4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)propyl)phosphonate;

Diethyl ((4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)phosphonate;
3-(4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)propanoic acid;
4-(4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)butanoic acid;

N-(4-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)phenyl)acetamide;

4-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzo[c][1,2]oxaborol-1(3H)-ol;

5-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzo[c][1,2]oxaborol-1(3H)-ol;

(4-((4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)phenyl)boronic acid;

2-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

3-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(4-Bromophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(4-Chlorophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(3,4-Dichlorophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(4-(Trifluoromethyl)phenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(3,4-Dimethoxyphenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(4-Acetamidophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(4-Benzamidophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

1,1-Dimethyl-4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-ium Iodide

trans-2-Phenyl-N-((1-phenylpiperidin-4-yl)methyl)cyclopropanamine;

Ethyl 4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxylate;

trans-4-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)cyclohexanecarboxylic acid;

3-(4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)propanoic acid;

trans-N,N-Dimethyl-4-(((trans-2-phenylcyclopropyl)amino)methyl)cyclohexanamine;
N-(trans-4-(((trans-2-Phenylcyclopropyl)amino)methyl)cyclohexyl)acetamide;
N-(trans-4-(((trans-2-Phenylcyclopropyl)amino)methyl)cyclohexyl)benzamide;
4-(((trans-4-(((trans-2-Phenylcyclopropyl)amino)methyl)cyclohexyl)amino)methyl)benzoic acid;
4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidine;
trans-N-Methyl-2-phenyl-N-(2-(piperidin-4-yl)ethyl)cyclopropanamine;
trans-N-Methyl-N-((1-methylpiperidin-4-yl)methyl)-2-phenylcyclopropanamine;
trans-N-(1-Cyclohexylethyl)-2-phenylcyclopropanamine;
trans-Methyl 4-(((trans-2-phenylcyclopropyl)amino)methyl)cyclohexanecarboxylate;
trans-4-(((trans-2-Phenylcyclopropyl)amino)methyl)cyclohexanecarboxylic acid;
trans-4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)cyclohexanecarboxylic acid;
4-(((trans-2-(4-Benzamidophenyl)cyclopropyl)amino)methyl)cyclohexanecarboxylic acid;
4-(((trans-2-(4-Acetamidophenyl)cyclopropyl)amino)methyl)cyclohexanecarboxylic acid ;
trans-2-(3-Fluoro-2-methoxyphenyl)-N-(piperidin-4-ylmethyl)cyclopropanamine;
trans-2-(2-(benzyloxy)-3-fluorophenyl)-N-(piperidin-4-ylmethyl)cyclopropanamine;
trans-2-(3,5-difluorophenyl)-N-(piperidin-4-ylmethyl)cyclopropanamine;
trans-2-(2,5-difluorophenyl)-N-(piperidin-4-ylmethyl)cyclopropanamine;
N-(4-((trans)-2-((Piperidin-4-ylmethyl)amino)cyclopropyl)phenyl)acetamide;
N-(4-((trans)-2-((piperidin-4-ylmethyl)amino)cyclopropyl)phenyl)methanesulfonamide;
N-(4-((trans)-2-((piperidin-4-ylmethyl)amino)cyclopropyl)phenyl)benzenesulfonamide;
N-(4-((trans)-2-((piperidin-4-ylmethyl)amino)cyclopropyl)phenyl)benzamide;
(trans)-N-((1-(Methylsulfonyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;
N-ethyl-4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxamide;

N-cyclopropyl-4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxamide;
N;N-dimethyl-4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxamide;
(4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)(pyrrolidin-1-yl)methanone;
trans-N-((1-(cyclopropylsulfonyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;
trans-N-((1-(isopropylsulfonyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;
trans-N-((1-((3,5-dimethylisoxazol-4-yl)sulfonyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;
trans-N-((1-((1,2-dimethyl-1H-imidazol-4-yl)sulfonyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;
(trans)-N-(2-(1-Methylpiperidin-4-yl)ethyl)-2-phenylcyclopropanamine;
(trans)-2-Phenyl-N-(2-(1-(pyridin-2-yl)piperidin-4-yl)ethyl)cyclopropanamine;
6-(4-(2-(((trans)-2-Phenylcyclopropyl) amino) ethyl) piperidin-1-yl) nicotinic acid;
trans-2-phenyl-N-(2-(1-(pyridin-4-yl)piperidin-4-yl)ethyl)cyclopropanamine;
trans-2-phenyl-N-(2-(1-(pyrimidin-4-yl)piperidin-4-yl)ethyl)cyclopropanamine;
trans-2-phenyl-N-(2-(1-phenylpiperidin-4-yl)ethyl)cyclopropanamine;
trans-2-phenyl-N-(2-(1-(pyridin-3-yl)piperidin-4-yl)ethyl)cyclopropanamine;
trans-2-phenyl-N-(2-(1-(pyrimidin-2-yl)piperidin-4-yl)ethyl)cyclopropanamine;
trans-N-(2-(1-(2-methoxyethyl)piperidin-4-yl)ethyl)-2-phenylcyclopropanamine;
trans-N-(2-(1-isopropylpiperidin-4-yl)ethyl)-2-phenylcyclopropanamine;
3-Cyano-4-((4-((((trans)-2-phenylcyclopropyl) amino)methyl)piperidin-1-yl)methyl)benzoic acid;
2-fluoro-4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;
3-fluoro-4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;
3-chloro-4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;
3-methoxy-4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

2-chloro-4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;
4-(3-(4-(Cyano(((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzoic acid;
4-{3-[4-({[(trans))-2-phenylcyclopropyl]amino}methyl)-1-piperidinyl]propyl}benzoic acid;
4-(4-(4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)butyl)benzoic acid;
4-(4-(4-(Cyano(((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)butyl)benzoic acid;
4-(2-(4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)ethyl)benzoic acid;
4-(2-(4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)ethyl)benzoic acid;
6-((4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)-2-naphthoic acid;
6-((4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)-2-naphthoic acid;
(trans)-N-((1-(4-(1H-Tetrazol-5-yl)benzyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;
2-(4-((4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzamido)acetic acid;
N-(4-((4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)phenyl)methanesulfonamide;
(trans)-N-((1-(3-(1H-Tetrazol-5-yl)propyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;
4-((4-(2-(((trans)-2-Phenylcyclopropyl)amino)ethyl)piperidin-1-yl)methyl)benzoic acid ;
2,2-Dimethyl-3-(4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)propanoic acid ;
6-((4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)nicotinic acid;
2-(4-((4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)phenyl)acetic acid;

2-((4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)oxazole-4-carboxylic acid;

2-(4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)phenoxy)acetic acid;

N-(Methylsulfonyl)-4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzamide ;

4-((4-((((trans)-2-(4-Iodophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((trans)-2-(((1-Benzylpiperidin-4-yl)methyl)amino)cyclopropyl)benzoic acid ;

4-((4-((((trans)-2-(4-(1-Methyl-1H-pyrazol-4-yl)phenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-((((trans)-2-(4-Cyclopropylphenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

1-Methyl-4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidine-4-carboxylic acid

4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidine-4-carboxylic acid;

1-Benzyl-4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidine-4-carboxylic acid;

2-Chloro-4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

3-(3-(4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzoic acid;

4-(3-(2-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)morpholino)propyl)benzoic acid;

4-((2-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)morpholino)methyl)benzoic acid;

3-(3-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)pyrrolidin-1-yl)propanoic acid;

2-(4-((4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)phenyl)acetic acid; and

3-((R)-3-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)pyrrolidin-1-yl)propanoic acid; or a pharmaceutically acceptable salt thereof.

18. A compound of claim 14 selected from the group consisting of:

1,1-dimethylethyl 4-({[*trans*-2-phenylcyclopropyl]amino}methyl)-1-piperidinecarboxylate;

1,1-dimethylethyl 4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)-1-piperidinecarboxylate;

1,1-dimethylethyl 4-({[(1S,2R)-2-phenylcyclopropyl]amino}methyl)-1-piperidinecarboxylate;

[*trans*-2-phenylcyclopropyl](4-piperidinylmethyl)amine;

[(1S,2R)-2-phenylcyclopropyl](4-piperidinylmethyl)amine;

[(1R,2S)-2-phenylcyclopropyl](4-piperidinylmethyl)amine;

trans-N-(cyclohexylmethyl)-2-phenylcyclopropanamine;

[*trans*-2-phenylcyclopropyl]{[1-(phenylmethyl)-4-piperidinyl]methyl}amine;

1,1-cimethylethyl [*trans*-4-({[trans-2-phenylcyclopropyl]amino}methyl)cyclohexyl]carbamate;

trans-4-({[trans-2-Phenylcyclopropyl]amino}methyl)cyclohexanamine;

2-(4-(((*trans*-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)ethanol;

N-phenyl-4-(((*trans*-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxamide;

phenyl(4-(((*trans*-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methanone;

1-(4-(((*trans*-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)ethanone;

[*trans*-2-Phenylcyclopropyl](3-piperidinylmethyl)amine;

N-(*trans*-2-phenylcyclopropyl)-N-(piperidin-4-ylmethyl)acetamide;

benzyl 4-(((*trans*-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxylate;

4-(((*trans*-2-Phenylcyclopropyl)amino)methyl)piperidine;

[(1-methyl-4-piperidinyl)methyl][*trans*-2-phenylcyclopropyl]amine;

1,1-dimethylethyl 4-({[*trans*-2-phenylcyclopropyl]amino}methyl)hexahydro-1*H*-azepine-1-carboxylate;

N-(hexahydro-1*H*-azepin-4-ylmethyl)-trans-2-phenylcyclopropanamine;

[*trans*-2-phenylcyclopropyl][2-(4-piperidinyl)ethyl]amine;

[*trans*-2-phenylcyclopropyl][1-(4-piperidinyl)ethyl]amine; and

N-(2-morpholinylmethyl)-*trans*-2-phenylcyclopropanamine; or a pharmaceutically acceptable salt thereof.

19. A compound of claim 14 selected from the group consisting of:

N-(hexahydro-1*H*-azepin-4-ylmethyl)-trans-2-phenylcyclopropanamine;
[*trans*-2-phenylcyclopropyl][2-(4-piperidinyl)ethyl]amine;
[*trans*-2-phenylcyclopropyl][1-(4-piperidinyl)ethyl]amine;
N-(2-morpholinylmethyl)-*trans*-2-phenylcyclopropanamine; and
3-((R)-3-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)pyrrolidin-1-yl)propanoic acid;

or a pharmaceutically acceptable salt thereof.


20. A pharmaceutical composition comprising a compound according to any one of claims 1-19 and a pharmaceutically acceptable carrier.

21. A method of treating cancer which comprises administering to a human in need thereof an effective amount of a compound as described in any one of claims 1-20.


22. A method of claim 21, wherein the cancer is selected from the group consisting of: brain (gliomas), glioblastomas, leukemias, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, inflammatory breast cancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma, medulloblastoma, colon, head and neck, kidney, lung, liver, melanoma, renal, ovarian, pancreatic, prostate, sarcoma, osteosarcoma, giant cell tumor of bone and thyroid.

CLAIMS

1. A compound of Formula (IV) or Formula (V):



(IV)



(V)

wherein:

R_1 is selected from the group consisting of C_1-C_6alkyl, -$NHSO_2Me$, -$NHSO_2Ph$, arylalkoxy, C_3-C_7cycloalkyl, -$NHC(O)R_a$, 1-methyl-1H-pyrazol-4-yl, hydroxyl, C_1-C_4alkoxy, halogen, -NR'R'', and -$C(O)OR_a$;

R_3 is selected from the group consisting of aryl, heteoaryl, -SO_2R_a, -$NHC(O)R_a$, -$CH_2C(O)OR_a$, -$C(O)OR_a$, -$C(O)R_a$, -$C(O)NR_aR_b$, -NR'R'', arylalkyl, and heteroarylalkyl;

each R_a is independently hydrogen, phenyl, phenylmethyl, 3,5-dimethylisoxazol-4-yl, 1,2-dimethyl-1H-imidazol-4-yl, C_3-C_7cycloalkyl, or C_1-C_6alkyl;

R_b is hydrogen or C_1-C_3alkyl; or

R_a and R_b together form a 5- or 6-membered heterocycloalkyl ring;

each R' and R" is independently selected from a group including hydrogen, unsubstituted C_1-C_6alkyl, -C(O)R_c, and unsubstituted C_3-C_7cycloalkyl; wherein R_c is unsubstituted C_1-C_6alkyl, unsubstituted C_3-C_7cycloalkyl, or unsubstituted C_3-C_6heterocyclyl;

R_4 is H;

W is -$(CH_2)_{1-4}$ or -$CH(R_c)(CH_2)_{0-3}$, in which R_c is -CN or C_1-C_4alkyl;

X is N;

Z is $(CH_2)_q$, wherein q is 0-2, and wherein when q is 0, Z represents a bond; and

m is 0-3;

or a pharmaceutically acceptable salt thereof.


2. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein R_1 is F, Cl, C_1-C_4alkoxy, or C_1-C_4alkyl.

3. The compound or pharmaceutically acceptable salt thereof according to claim 1, wherein m is 0.

4. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-3, wherein R_3 is selected from the group consisting of aryl, arylalkyl, heteoaryl, and heteroarylalkyl, wherein any said aryl or heteroaryl are each optionally substituted with one, two, or three groups selected from the group consisting of -COOH, C_1-C_4alkoxy, -C(O)OC_1-C_4alkyl, C_1-C_4alkyl, halogen, -CN, tetrazolyl, -$NHSO_2Me$, -SO_2Me, -$C(O)NHSO_2Me$, and -OCH_2COOH.

5. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1-3, wherein R_3 is selected from the group consisting of -SO_2R_a, -C(O)OR_a, -C(O)R_a, -C(O)NR_aR_b, arylalkyl, and heteroarylalkyl, wherein R_a is phenyl, phenylmethyl, C_3-C_7cycloalkyl, or C_1-C_6alkyl; and R_b is hydrogen or C_1-C_4alkyl.

6. The compound or pharmaceutically acceptable salt thereof according to claim 1, which is represented by Formula (VI):



(VI)

R_1 is selected from the group consisting of C_1-C_6alkyl, -$NHSO_2Me$, -$NHSO_2Ph$, arylalkoxy, C_3-C_7cycloalkyl, -$NHC(O)R_a$, 1-methyl-1H-pyrazol-4-yl, hydroxyl, C_1-C_4alkoxy, halogen, -NR'R'', and -$C(O)OR_a$;

each R_a is independently hydrogen, phenyl, phenylmethyl, 3,5-dimethylisoxazol-4-yl, 1,2-dimethyl-1H-imidazol-4-yl, C_3-C_7cycloalkyl, or C_1-C_6alkyl;

each R' and R" is independently selected from a group including hydrogen, unsubstituted C_1-C_6alkyl, -$C(O)R_c$, and unsubstituted C_3-C_7cycloalkyl; wherein R_c is unsubstituted C_1-C_6alkyl, unsubstituted C_3-C_7cycloalkyl, or unsubstituted C_3-C_6heterocyclyl;


W is -$(CH_2)_{1-4}$ or -$CH(R_c)(CH_2)_{0-3}$, in which R_c is -CN or C_1-C_4alkyl;

s is 1 or 2;

m is 0 or 1; and

each R_5 is independently selected from the group consisting of: -COOH, C_1-C_4alkoxy, -$C(O)OC_1$-C_4alkyl, C_1-C_4alkyl, halogen, CN, tetrazolyl, -$NHSO_2Me$, -SO_2Me, -$C(O)NHSO_2Me$, and -OCH_2COOH.

7. The compound or pharmaceutically acceptable salt thereof according to claim 1, which is represented by Formula (VII):



(VII)

R_1 is selected from the group consisting of C_1-C_6alkyl, -$NHSO_2Me$, -$NHSO_2Ph$, arylalkoxy, C_3-C_7cycloalkyl, -$NHC(O)R_a$, 1-methyl-1H-pyrazol-4-yl, hydroxyl, C_1-C_4alkoxy, halogen, -NR'R'', and -$C(O)OR_a$;

each R_a is independently hydrogen, phenyl, phenylmethyl, 3,5-dimethylisoxazol-4-yl, 1,2-dimethyl-1H-imidazol-4-yl, C_3-C_7cycloalkyl, or C_1-C_6alkyl;

each R' and R" is independently selected from a group including hydrogen, unsubstituted C_1-C_6alkyl, -$C(O)R_c$, and unsubstituted C_3-C_7cycloalkyl; wherein R_c is unsubstituted C_1-C_6alkyl, unsubstituted C_3-C_7cycloalkyl, or unsubstituted C_3-C_6heterocyclyl;

W is -$(CH_2)_{1-4}$ or -$CH(R_c)(CH_2)_{0-3}$, in which R_c is -CN or C_1-C_4alkyl;

s is 1 or 2;

m is 0 or 1; and

each R_5 is independently selected from the group consisting of: -COOH, C_1-C_4alkoxy, -$C(O)OC_1$-C_4alkyl, C_1-C_4alkyl, halogen, CN, tetrazolyl, -$NHSO_2Me$, -SO_2Me, -$C(O)NHSO_2Me$, and -OCH_2COOH.

8. The compound or pharmaceutically acceptable salt thereof according to claim 6, wherein s is 1 and R_5 is -COOH.

9. The compound or pharmaceutically acceptable salt thereof according to claim 7, wherein s is 1 and R_5 is -COOH.

10. The compound according to claim 1 which is:

1,1-Dimethylethyl 4-({[*trans*-2-phenylcyclopropyl]amino}methyl)-1-piperidinecarboxylate;

1,1-Dimethylethyl 4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)-1-piperidinecarboxylate;

1,1-Dimethylethyl 4-({[(1S,2R)-2-phenylcyclopropyl]amino}methyl)-1-piperidinecarboxylate;

[*trans*-2-Phenylcyclopropyl]{[1-(phenylmethyl)-4-piperidinyl]methyl}amine;

N-Phenyl-4-(((*trans*-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxamide;

Phenyl(4-(((*trans*-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methanone;

1-(4-(((*trans*-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)ethanone;

Benzyl 4-(((*trans*-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxylate;

1,1-Dimethylethyl 4-({[*trans*-2-phenylcyclopropyl]amino}methyl)hexahydro-1*H*-azepine-1-carboxylate

2-(4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)acetic acid;

4-{[(3*R*)-3-({[(1*R*,2*S*)-2-Phenylcyclopropyl]amino}methyl)-1-pyrrolidinyl]methyl}benzoic acid ;

4-{[(3*S*)-3-({[(1*R*,2*S*)-2-Phenylcyclopropyl]amino}methyl)-1-pyrrolidinyl]methyl}benzoic acid;

4-{3-[4-({[(1*R*,2*S*)-2-Phenylcyclopropyl]amino}methyl)-1-piperidinyl]propyl}benzoic acid;

trans-2-Phenyl-N-((1-(pyridin-4-ylmethyl)piperidin-4-yl)methyl)cyclopropanamine;

trans-N-((1-(2-Fluorobenzyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

trans-N-((1-(3-Fluorobenzyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

trans-N-((1-(4-Fluorobenzyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

trans-N-((1-(2,4-Difluorobenzyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

Ethyl 4-((4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoate;

trans-N-((1-(4-(Methylsulfonyl)benzyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

2-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzonitrile;

trans-2-Phenyl-N-((1-(2-(trifluoromethyl)benzyl)piperidin-4-yl)methyl)cyclopropanamine;

trans-N-((1-((5-Methylisoxazol-3-yl)methyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

trans-N-((1-((1H-Pyrazol-4-yl)methyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine

N-(4-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)phenyl)acetamide;

4-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzo[c][1,2]oxaborol-1(3H)-ol;

5-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzo[c][1,2]oxaborol-1(3H)-ol;

(4-((4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)phenyl)boronic acid;

2-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

3-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(4-Bromophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(4-Chlorophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(3,4-Dichlorophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(4-(Trifluoromethyl)phenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(3,4-Dimethoxyphenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(4-Acetamidophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-(((trans-2-(4-Benzamidophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

trans-2-Phenyl-N-((1-phenylpiperidin-4-yl)methyl)cyclopropanamine;

Ethyl 4-(((trans-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxylate;

trans-4-((4-(((trans-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)cyclohexanecarboxylic acid;

(trans)-N-((1-(Methylsulfonyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

N-ethyl-4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxamide;

N-cyclopropyl-4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxamide;

N;N-dimethyl-4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidine-1-carboxamide;

(4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)(pyrrolidin-1-yl)methanone;

trans-N-((1-(cyclopropylsulfonyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

trans-N-((1-(isopropylsulfonyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

trans-N-((1-((3,5-dimethylisoxazol-4-yl)sulfonyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

trans-N-((1-((1,2-dimethyl-1H-imidazol-4-yl)sulfonyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

(trans)-2-Phenyl-N-(2-(1-(pyridin-2-yl)piperidin-4-yl)ethyl)cyclopropanamine;

6-(4-(2-(((trans)-2-Phenylcyclopropyl) amino) ethyl) piperidin-1-yl) nicotinic acid;

trans-2-phenyl-N-(2-(1-(pyridin-4-yl)piperidin-4-yl)ethyl)cyclopropanamine;

trans-2-phenyl-N-(2-(1-(pyrimidin-4-yl)piperidin-4-yl)ethyl)cyclopropanamine;

trans-2-phenyl-N-(2-(1-phenylpiperidin-4-yl)ethyl)cyclopropanamine;

trans-2-phenyl-N-(2-(1-(pyridin-3-yl)piperidin-4-yl)ethyl)cyclopropanamine;

trans-2-phenyl-N-(2-(1-(pyrimidin-2-yl)piperidin-4-yl)ethyl)cyclopropanamine;

3-Cyano-4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

2-fluoro-4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

3-fluoro-4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

3-chloro-4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

3-methoxy-4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

2-chloro-4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-(3-(4-(Cyano(((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzoic acid;

4-{3-[4-({[(trans))-2-phenylcyclopropyl]amino}methyl)-1-piperidinyl]propyl}benzoic acid;

4-(4-(4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)butyl)benzoic acid;

4-(4-(4-(Cyano(((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)butyl)benzoic acid;

4-(2-(4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)ethyl)benzoic acid;

4-(2-(4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)ethyl)benzoic acid;

6-((4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)-2-naphthoic acid;

6-((4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)-2-naphthoic acid;

(trans)-N-((1-(4-(1H-Tetrazol-5-yl)benzyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

2-(4-((4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzamido)acetic acid;

N-(4-((4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)phenyl)methanesulfonamide;

(trans)-N-((1-(3-(1H-Tetrazol-5-yl)propyl)piperidin-4-yl)methyl)-2-phenylcyclopropanamine;

4-((4-(2-(((trans)-2-Phenylcyclopropyl)amino)ethyl)piperidin-1-yl)methyl)benzoic acid;

6-((4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)nicotinic acid;

2-(4-((4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)phenyl)acetic acid;

2-((4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)oxazole-4-carboxylic acid;

2-(4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)phenoxy)acetic acid;

N-(Methylsulfonyl)-4-((4-((((trans)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzamide ;

4-((4-((((trans)-2-(4-Iodophenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((trans)-2-(((1-Benzylpiperidin-4-yl)methyl)amino)cyclopropyl)benzoic acid ;

4-((4-((((trans)-2-(4-(1-Methyl-1H-pyrazol-4-yl)phenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

4-((4-((((trans)-2-(4-Cyclopropylphenyl)cyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;


2-Chloro-4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid;

3-(3-(4-((((trans)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)propyl)benzoic acid; or

2-(4-((4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)phenyl)acetic acid;

or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 1 which is 4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid, represented by the formula:



;

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to any one of claims 1-11 and a pharmaceutically acceptable excipient.

13. Use of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1-11 in preparation of a medicament for treating cancer.

14. The use of claim 13, wherein the cancer is selected from the group consisting of: brain (gliomas), glioblastomas, leukemias, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, inflammatory breast cancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma, medulloblastoma, colon, head and neck, kidney, lung, liver, melanoma, renal, ovarian, pancreatic, prostate, sarcoma, osteosarcoma, giant cell tumor of bone and thyroid.